A 245-patient real-world study found that immune effector cell-associated hematotoxicity (ICAHT) after BCMA-directed CAR-T therapy was less frequent when treatment occurred after one to three prior lines rather than four or more lines, but…
A University of Colorado-led preprint reports that overexpressing the actin regulator Formin-like 1 (FMNL1) in tumor-specific T cells increases accumulation in restrictive solid tumors and improves antitumor activity in mouse models. The intervention is…
A Nature Medicine study documented 4-1BB-costimulated CD19 CAR-T cells up to 10 years after infusion in adults with B-cell non-Hodgkin lymphoma. Among eight evaluable patients who remained in remission beyond five years, the CAR…
A single-center study of 104 recipients of commercial CD19- or BCMA-directed CAR-T found that overall clonal hematopoiesis (CHIP) was not associated with toxicity, progression-free survival or overall survival. The signal emerged only after genotype…
A French nationwide registry analysis of 1,542 adults with large B-cell lymphoma clarifies how response evolves after CD19 CAR-T therapy. At one month, 49.1% of patients were in complete remission, while 35.5% of the…
Researchers at UCL and Great Ormond Street Hospital have published first-in-human feasibility data for BE-CAR33 in Science Translational Medicine, a donor-derived, “off-the-shelf” anti-CD33 CAR-T cell therapy engineered using multiplex cytosine base editing to disrupt…
